CORCEPT THERAPEUTICS INC (CORT) Cash and securities
- Total cash · latest quarter (USD): Value $308.20M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $308.20M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $111.04M + $197.16M ≈ $308.20M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 111.04M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 197.16M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Cash and current securities | 308.20M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $308.20M | (m) | $111.04M | $197.16M | (m) |
| 2026-03-31 | $338.18M | (m) | $108.74M | $229.45M | (m) |
| 2025-12-31 | $372.15M | (m) | $120.50M | $251.66M | (m) |
| 2025-09-30 | $421.68M | (m) | $125.14M | $296.55M | (m) |
| 2025-06-30 | $342.23M | (m) | $102.75M | $239.48M | (m) |
| 2025-03-31 | $322.76M | (m) | $89.82M | $232.94M | (m) |
| 2024-12-31 | $383.33M | (m) | $127.67M | $255.67M | (m) |
| 2024-09-30 | $380.34M | (m) | $137.29M | $243.05M | (m) |
| 2024-06-30 | $473.16M | (m) | $128.59M | $344.57M | (m) |
| 2024-03-31 | $410.76M | (m) | $149.75M | $261.01M | (m) |
| 2023-12-31 | $368.22M | (m) | $135.55M | $232.67M | (m) |
| 2023-09-30 | $355.23M | (m) | $111.80M | $243.43M | (m) |
| 2023-06-30 | $363.26M | (m) | $172.38M | $190.88M | (m) |
| 2023-03-31 | $465.06M | (m) | $299.94M | $165.12M | (m) |
| 2022-12-31 | $431.67M | (m) | $66.33M | $365.34M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $346.02M | (m) |
| 2022-06-30 | $370.09M | (m) | $35.35M | $334.74M | (m) |
| 2022-03-31 | $345.53M | (m) | $61.86M | $283.67M | (m) |
| 2021-12-31 | $223.53M | (m) | $77.62M | $145.92M | (m) |
| 2021-09-30 | $361.33M | (m) | $94.69M | $266.64M | (m) |
| 2021-06-30 | $369.98M | (m) | $95.43M | $274.55M | (m) |
| 2021-03-31 | $372.96M | (m) | $52.38M | $320.58M | (m) |
| 2020-12-31 | $440.70M | (m) | $76.19M | $364.51M | (m) |
| 2020-09-30 | $428.79M | (m) | $30.56M | $398.23M | (m) |
| 2020-06-30 | $405.36M | (m) | $58.52M | $346.83M | (m) |
| 2020-03-31 | $307.31M | (m) | $84.48M | $222.84M | (m) |
| 2019-12-31 | $275.96M | (m) | $31.27M | $244.69M | (m) |
| 2019-09-30 | $231.65M | (m) | $44.95M | $186.70M | (m) |
| 2019-06-30 | $201.54M | (m) | $58.14M | $143.40M | (m) |
| 2019-03-31 | $186.91M | (m) | $49.65M | $137.25M | (m) |
| 2018-12-31 | $206.76M | (m) | $41.63M | $165.13M | (m) |
| 2018-09-30 | $195.19M | (m) | $33.89M | $161.30M | (m) |
| 2018-06-30 | $159.94M | (m) | $31.16M | $128.78M | (m) |
| 2018-03-31 | $125.36M | (m) | $33.12M | $92.24M | (m) |
| 2017-12-31 | $88.74M | (m) | $31.06M | $57.68M | (m) |
| 2017-09-30 | $75.16M | (m) | $31.06M | $44.10M | (m) |
| 2017-06-30 | $66.17M | (m) | $33.62M | $32.54M | (m) |
| 2017-03-31 | $52.77M | (m) | $37.98M | $14.80M | (m) |
| 2016-12-31 | (m) | (m) | $51.54M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $47.87M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $41.79M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $40.74M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $40.44M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $36.45M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $37.05M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $37.95M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $24.25M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $26.78M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $33.97M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $43.62M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $54.88M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $63.17M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $72.22M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $81.46M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $93.03M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $101.63M | (m) | (m) |
| 2012-06-30 | (m) | (m) | $34.90M | (m) | (m) |
| 2012-03-31 | (m) | (m) | $42.63M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $39.63M | (m) | (m) |
| 2011-09-30 | (m) | (m) | $45.91M | (m) | (m) |
| 2011-06-30 | (m) | (m) | $52.23M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $59.20M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $24.58M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $28.98M | (m) | (m) |
| 2010-06-30 | (m) | (m) | $35.38M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $23.87M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $14.72M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |